Delivery Order SPE2DB24D2105-SPE2DB25FAQAS
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Ondansetron ODT 8 mg tablets in quantities of 30, with a contract ceiling value of $2,831.66. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract is scheduled for ultimate completion on July 29, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a ceiling value of $8,001.71. This is a firm fixed price, non-competitive delivery order executed under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The order will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron ODT 4 MG tablets (30-count) with a contract ceiling value of $1,512.72. This firm fixed price delivery order, which is set to be completed by August 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The award was competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron ODT 8 mg tablets in a 30-count package, with a ceiling value of $1,726.44. This firm fixed-price delivery order, which is set to be completed by August 5, 2025, represents a continuation of AmerisourceBergen's pharmaceutical supply role under its larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract does not carry a set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Ondansetron HCL 8 MG tablets (30-count packaging) with a ceiling value of $1,830.06. This firm fixed-price delivery order, which is expected to be completed by August 5, 2025, carries no set-aside designation and was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,884.12 on July 24, 2025, for the supply of Ondansetron HCl 8 mg tablets (30-count packaging). This is a firm fixed-price, non-set-aside contract with performance completion scheduled for July 25, 2025, and fulfillment based in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a $7,527.37 delivery order to AmerisourceBergen Drug Corp for Ondansetron ODT 8 mg tablets (30-count supply) on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The contract carries no set-aside...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ondansetron ODT 4 mg tablets in a quantity of 30 units, with a ceiling value of $13,637.20. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. AmerisourceBergen Drug Corp, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Ondansetron ODT 4 mg tablets (30-count units) with a contract ceiling value of $3,874.25. This is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and represents a non-competitive set-aside award. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,882.56 to AmerisourceBergen Drug Corp for the supply of Ondansetron ODT 4 mg tablets (30-count units). This is a firm fixed price delivery order with no set-aside designation, competitively awarded and completed on August 8, 2025. The contract was performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQASDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ondansetron HCL 8 mg tablets in quantities of 30 tablets, with a ceiling value of $20,173.94. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is being performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, and is scheduled for completion by August 8, 2025. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical vendor for federal medical procurement through its comprehensive pharmaceutical and medical supply portfolio. The company's DLA IDC functions as a global pharmaceutical support vehicle enabling the delivery of brand-name and generic medications, vaccines, specialty drugs, and medical supplies to support military healthcare programs and other federal health systems worldwide. The current delivery order for Ondansetron—an anti-nausea medication commonly used in military and veteran healthcare settings—exemplifies the company's role in supplying essential pharmaceuticals to the Defense Health Agency and related federal customers through this flexible contracting mechanism.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.2k | 8/7/25 |